TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please no advertisers. This is a free site for all.
Thank you.


Wednesday, April 12, 2017

Add-On Medical Food Beneficial in Advanced Parkinson's Disease

April 12, 2017  
Da Hee Han, PharmD




Findings from a study published in CNS & Neurological Disorders - Drug Targets reported that ultra-micronized palmitoylethanolamide (um-PEA) slowed disease progression and disability when used as adjunct therapy in advanced Parkinson's disease patients. 
Previous animal model studies have shown PEA, an endogenous fatty acid signaling molecule, to be beneficial in neuroinflammation and provide neuroprotection. In this study, researchers from San Giuseppe Hospital, Florence, Italy, studied um-PEA in 30 patients with diagnosed Parkinson's disease. 
Study patients (mean age: 73 years) were receiving L-DOPA daily and other Parkinson's disease treatmentswere evaluated monthly over 3 consecutive months. They were then given the medical food um-PEA (marketed as Normast) 1200mg daily for 3 months followed by 600mg daily for up to 12 months. Patients' motor and non-motor symptoms were assessed by the MDS-UPDRS questionnaire and they underwent further clinical assessment at Months 1, 3, 6, and 12.  
When used as add-on therapy to L-DOPA, um-PEA resulted in a significant and progressive reduction of total score in Non-Motor Aspects of Experiences of Daily Living from baseline to Month 12 (from 9.7 to 4.5). Also, treatment with um-PEA for 1 year showed significant and progressive reduction in the average Motor Aspects of Experiences of Daily Living total score from baseline to Month 12 (from 12.7 to 7.6). The average total motor complication score was also reduced from 8.8 at baseline to 4.2 after 12 months of add-on um-PEA. 
Study authors reported no treatment-related adverse effects. They concluded that um-PEA was a safe and effective adjuvant therapy in patients with advanced Parkinson's disease receiving L-DOPA. 
http://www.empr.com/news/ultra-micronized-palmitoylethanolamide-parkinsons-disease-neuroinflammation/article/650003/

No comments:

Post a Comment